Revenue Breakdown
Composition ()
No data
Revenue Streams
Novartis AG (NVS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Rest of portfolio, accounting for 17.9% of total sales, equivalent to $2.35B. Other significant revenue streams include Immunology - Cosentyx and Oncology -Kisqali. Understanding this composition is critical for investors evaluating how NVS navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Novartis AG maintains a gross margin of 74.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.45%, while the net margin is 23.36%. These profitability ratios, combined with a Return on Equity (ROE) of 35.21%, provide a clear picture of how effectively NVS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NVS competes directly with industry leaders such as AZN and ONC. With a market capitalization of $277.11B, it holds a significant position in the sector. When comparing efficiency, NVS's gross margin of 74.55% stands against AZN's 82.46% and ONC's 88.95%. Such benchmarking helps identify whether Novartis AG is trading at a premium or discount relative to its financial performance.
